# Alisertib

Source: https://onco.cc/drugs/alisertib/  
OnCo record `alisertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer.

## Summary

Alisertib is listed on ClinicalTrials.gov as an intervention in 5 registered phase 2 trials sponsored by Puma Biotechnology, Inc., in small-cell lung cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: PB-8237; MLN8237
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral serine/threonine kinase inhibitor
- Mechanism: A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.

## Sources

- ClinicalTrials.gov: trials of Alisertib: https://clinicaltrials.gov/search?intr=Alisertib

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Puma Biotechnology](https://onco.cc/companies/puma-biotechnology/)
- trials: [A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)](https://onco.cc/trials/nct07465757/), [A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct06369285/), [A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06095505/)

---
JSON: https://onco.cc/api/v1/entities/alisertib.json